18F-mFBG
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroblastoma
Conditions
Neuroblastoma, Pheochromocytoma, Paraganglioma
Trial Timeline
Jan 1, 2025 → Dec 1, 2025
NCT ID
NCT06233903About 18F-mFBG
18F-mFBG is a phase 2 stage product being developed by Illumina for Neuroblastoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06233903. Target conditions include Neuroblastoma, Pheochromocytoma, Paraganglioma.
What happened to similar drugs?
0 of 1 similar drugs in Neuroblastoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07176286 | Phase 2 | Recruiting |
| NCT06233903 | Phase 2 | Withdrawn |
| NCT04724369 | Phase 3 | Completed |
Competing Products
20 competing products in Neuroblastoma